Cited by 830Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

Sequist, Lecia V., Martins, Renato G., Spigel, David, Grunberg, Steven M., Spira, Alexander, Jänne, Pasi A., Joshi, Victoria A., McCollum, David, Evans, Tracey L., Muzikansky, Alona, Kuhlmann, Georgiana L., Han, Moon, Goldberg, Jonathan S., Settleman, Jeffrey, Iafrate, A. John, Engelman, Jeffrey A., Haber, Daniel A., Johnson, Bruce E., Lynch, Thomas J.·2008·Journal of Clinical Oncology

DOI 10.1200/jco.2007.14.8494

Open this paper in CoChat — free account

Abstract

PURPOSE: Somatic mutations in the epidermal growth factor receptor (EGFR) correlate with increased response in patients with non-small-cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitors (TKIs). The multicenter iTARGET trial prospectively examined first-line gefitinib in advanced NSCLC patients harboring EGFR mutations and explored the significance of EGFR mutation subtypes and TKI resistance mechanisms. PATIENTS AND METHODS: Chemotherapy-naïve patients with advanced NSCLC with >or= 1 clinical characteristic associated with EGFR mutations underwent direct DNA sequencing of tumor tissue EGFR exons 18 to 21. Patients found to harbor any EGFR mutation were treated with gefitinib 250 mg/d until progression or unacceptable toxicity. The primary outcome was response rate. RESULTS: Ninety-eight patients underwent EGFR screening and mutations were detected in 34 (35%). EGFR mutations were primarily exon 19 deletions (53%) and L858R (26%) though 21% of mutation-positive cases had less common subtypes including exon 20 insertions, T790M/L858R, G719A, and L861Q. Thirty-one patients received gefitinib. The response rate was 55% (95% CI, 33 to 70) and median progression-free survival was 9.2 months (95% CI, 6.2 to 11.8). Therapy was well tolerated; 13% of patients had grade 3 toxicities including one grade 3 pneumonitis. Two patients with classic activating mutations exhibited de novo gefitinib resistance and had concurrent genetic anomalies usually associated with acquired TKI resistance, specifically the T790M EGFR mutation and MET amplification. CONCLUSION: First-line therapy with gefitinib administered in a genotype-directed fashion to patients with advanced NSCLC harboring EGFR mutations results in very favorable clinical outcomes with good tolerance. This strategy should be compared with combination chemotherapy, the current standard of care.

Integrity signals

Registry

Crossref · 10.1200/jco.2007.14.8494

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Self-citation
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citation
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citation
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citation
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Self-citation

Show all 46 references

Sorted by citations

Items 601–700 of 830

A Radiologist's Guide to the Changing Treatment Paradigm of Advanced Non–Small Cell Lung Cancer: The ASCO 2018 Molecular Testing Guidelines and Targeted Therapies
Chen, L., Smith, D. A., Somarouthu, B., Gupta, A. B., Gilani, K. A., & Ramaiya, N. H. (2019) · American Journal of Roentgenology · doi:10.2214/ajr.19.21135 · Cited by 9
Design, Synthesis, and Biological Evaluation of 1,2,4-Oxadiazole-Isoxazole Linked Quinazoline Derivatives as Anticancer Agents
Srinivas, M., Satyaveni, S., & Ram, B. (2019) · Russian Journal of General Chemistry · doi:10.1134/s1070363219120260 · Cited by 8
Some 2-(4-bromophenoxymethyl)-6-iodo-3-substituted quinazolin-4(3H)ones: Synthesis, cytotoxic activity, EGFR inhibition and molecular docking
Abbas, S. E.-S., Abdelgawad, N. M., George, R. F., Elyazid, M. G. A., Zaater, M. A., & El-Ashrey, M. K. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.133851 · Cited by 7
Reduced frequency dosing of osimertinib in EGFR-mutant non-small cell lung carcinoma: real world data
Noronha, V., Sahu, H., Kapoor, A., Patil, V. M., Menon, N. S., Shah, M. J., Davis, D., Roy, R., Srigadha, V. K., Janu, A., et al. (2024) · ecancermedicalscience · doi:10.3332/ecancer.2024.1721 · Cited by 7
Modern Drug Discovery and Development
Alexander, J. C., & Salazar, D. E. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-373639-0.00025-x · Cited by 7
Biomarkers in Oncology and Nephrology
Cen, P., Walther, C. P., Finkel, K. W., & Amato, R. J. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415948-8.00003-9 · Cited by 7
Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs
Lee, S. J., Sun, J., Lee, S., Ahn, J. S., Park, K., & Ahn, M. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.08.020 · Cited by 7
Genetics and Genomics in the Practice of Medicine
Joshi, V. A., & Kucherlapati, R. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.046 · Cited by 7
Self-citation
Is FISH floating or still swimming in the lung cancer ocean?
Cappuzzo, F., Camidge, D. R., & Varella‐Garcia, M. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq752 · Cited by 7
L858R-positive lung adenocarcinoma with KRAS G12V, EGFR T790M and EGFR L858R mutations: A case report
Xiang, X., YU, J., Lai, Y., He, W., Li, S., Wang, L., & Ke, Z. (2015) · Oncology Letters · doi:10.3892/ol.2015.3435 · Cited by 7
Gene expression profiles of ERCC1, TYMS, RRM1, TUBB3 and EGFR in tumor tissue from non-small cell lung cancer patients
Yu, D., Li, J., Han, Y., Shuku, L., Ning, X., Yunsong, L., Xiaojun, S., & Zhidong, L. (2014) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.20132949 · Cited by 7
Detection of Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma: Comparing Cobas 4800 EGFR Assay With Sanger Bidirectional Sequencing
Ardakani, N. M., Giardina, T. M., Grieu‐Iacopetta, F., Tesfai, Y., Carrello, A., Taylor, J. M. E., Robinson, C., Spagnolo, D. V., & Amanuel, B. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.02.002 · Cited by 7
A multi species evaluation of the radiation dosimetry of [ 11 C]erlotinib, the radiolabeled analog of a clinically utilized tyrosine kinase inhibitor
Petrulli, J. R., Hansen, S. B., Abourbeh, G., Yaqub, M. M., Bahce, I., Holden, D., Huang, Y. H., Nabulsi, N., Contessa, J. N., Mishani, E., et al. (2017) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2016.12.009 · Cited by 7
Increased EGFR mRNA Expression Levels in Non-Small Cell Lung Cancer
Taşdemir, Ş., Taheri, S., Akalın, H., Kontaş, O., Önal, Ö., & Özkul, Y. (2017) · Eurasian Journal of Medicine · doi:10.5152/eurasianjmed.2016.0237 · Cited by 7
Improved solubility of gefitinib achieved by the water-acetone solvate
Sun, Y. (2021) · Journal of the Indian Chemical Society · doi:10.1016/j.jics.2021.100260 · Cited by 7
Epidermal Growth Factor Receptor Exon 20 Mutation Increased inPost-Chemotherapy Patients with Non-Small Cell Lung Cancer Detected with Patients' Blood Samples
Wang, Y., Bao, W., Shi, H., Jiang, C., & Zhang, Y. (2013) · Translational Oncology · doi:10.1593/tlo.13391 · Cited by 7
Advances in the Chemopreventive Targeting of Oral Carcinogenesis
Wisniewski, D. J., Ma, T., & Schneider, A. (2015) · Current Oral Health Reports · doi:10.1007/s40496-015-0049-8 · Cited by 7
Differential MicroRNA Expression between EGFR T790M and L858R Mutated Lung Cancer
Kim, J. Y., Lee, W. J., Park, H. Y., Kim, A., Shin, D., & Lee, C. H. (2018) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2018.07.29 · Cited by 7
Optimizing response to gefitinib in the treatment of non-small-cell lung cancer
Normanno, N., Carotenuto, P., Roma, C., Rachiglio, A. M., Pasquale, R., Franco, R., Antinolfi, G., Piantedosi, Illiano, Botti, G., et al. (2011) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s6626 · Cited by 7
Lung adenocarcinoma surfaceome remodeling with EGFR inhibitors uncovers placental alkaline phosphatase as a target for combination therapy
Chen, Y., Dou, R., Hong, M. J., Xu, H., Vykoukal, J., Léon-Letelier, R. A., Cai, Y., Park, S., Irajizad, E., Hsiao, F. C., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102513 · Cited by 6
Investigational agents in the management of non-small cell lung cancer
Pennell, N. A., & Mekhail, T. M. (2009) · Current Oncology Reports · doi:10.1007/s11912-009-0039-x · Cited by 6
Recent Development of Molecular-Targeted Drugs in Lung Cancer
Saijo, N., & Kenmotsu, H. (2010) · Internal Medicine · doi:10.2169/internalmedicine.49.3845 · Cited by 6
Case 31-2011
Lanuti, M. D., Sequist, L. V. D., Sharma, A., & Mino-Kenudson, M. A. (2011) · New England Journal of Medicine · doi:10.1056/nejmcpc1013930 · Cited by 6
Self-citation
Clinicopathological features and outcomes in advanced nonsmall cell lung cancer with tailored therapy
Bala, S. C., Gundeti, S., Linga, V. G., Maddali, L. S., Digumarti, R., & Uppin, S. G. (2016) · Indian Journal of Medical and Paediatric Oncology · doi:10.4103/0971-5851.195735 · Cited by 6
Indian consensus statement for treatment of advanced non small cell lung cancer: First line, maintenance, and second line
Indian Cooperative Oncology Network (ICON) (2017) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_136_17 · Cited by 6
Comparison of INDEL Calling Tools with Simulation Data and Real Short-Read Data
Li, D., Kim, W., Wang, L., Yoon, K., Park, B., Park, C., Kong, S., Hwang, Y., Baek, D., Lee, E. S., et al. (2018) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2018.2854793 · Cited by 6
Intratumoral heterogeneity of copy number variation in lung cancer harboring L858R via immunohistochemical heterogeneous staining
Hashimoto, T., Osoegawa, A., Takumi, Y., Abe, M., Kobayashi, R., Miyawaki, M., Takeuchi, H., Okamoto, T., & Sugio, K. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.08.013 · Cited by 6
[Targeted Therapy and Mechanism of Drug Resistance in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor Gene Mutation].
Huang, J., & Wang, H. (2022) · PubMed · doi:10.3779/j.issn.1009-3419.2022.101.05 · Cited by 6
Scientific Challenges and Implementation Barriers to Translation of Pharmacogenomics in Clinical Practice
Lam, Y. W. F. (2014) · Apple Academic Press eBooks · doi:10.1201/b17137-6 · Cited by 6
Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Lung Cancer
Bearz, A., Cecco, S., Francescon, S., Re, F. L., Corona, G., & Baldo, P. (2019) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892814666190726124735 · Cited by 6
High frequency of exon 20 S768I EGFR mutation detected in malignant pleural effusions: A poor prognosticator of NSCLC
D′Souza, G., Dhar, C., Kyalanoor, V., Yadav, L., Sharma, M., Mohammad Nawaz, S., & Srivastava, S. (2020) · Cancer Reports · doi:10.1002/cnr2.1262 · Cited by 6
Hereditary Lung Cancer Risk: Recent Discoveries and Implications for Genetic Counseling and Testing
Koeller, D. R., Chen, R., & Oxnard, G. R. (2018) · Current Genetic Medicine Reports · doi:10.1007/s40142-018-0140-2 · Cited by 5
Modern Challenges for Early-Phase Clinical Trial Design and Biomarker Discovery in Metastatic Non-Small-Cell Lung Cancer
Rossi, A., Pilotto, S., Carbognin, L., Ferrara, M. G., Belluomini, L., Daniele, G., & Bria, E. (2021) · Journal of Molecular Pathology · doi:10.3390/jmp2030018 · Cited by 5
EGFR Mutation Detection in Brazilian Patients With Non–Small-Cell Lung Cancer: Lessons From Real-World Data Scenario of Molecular Testing
Montella, T. C., Zalis, M. G., Zukin, M., de Lima, V. C. C., Baldotto, C. S. D. R., Marchi, P. D., Salles, P. G. D. O., Mathias, C., Barrios, C. H., Kawamura, C., et al. (2023) · JCO Global Oncology · doi:10.1200/go.22.00426 · Cited by 5
Lung adenocarcinoma harboring L858R and T790M mutations in epidermal growth factor receptor, with poor response to gefitinib: A case report
WANG, Y. F., Xiang, X., Pei, X., Li, S., Tang, C., Wang, L., & Ke, Z. (2014) · Oncology Letters · doi:10.3892/ol.2014.2321 · Cited by 5
Molecular Pathology of Non–Small Cell Lung Cancer
Serracino, H. S., Franklin, W. A., & Aisner, D. L. (2012) · Surgical pathology clinics · doi:10.1016/j.path.2012.08.006 · Cited by 5
New targeted therapies for non-small-cell lung cancer
Metro, G., & Cappuzzo, F. (2009) · Therapy · doi:10.2217/thy.09.5 · Cited by 5
2010 Consensus on Lung Cancer, new clinical recommendations and current status of biomarker assessment — First-line therapy
Gridelli, C., Rossi, A., & Maione, P. (2011) · European Journal of Cancer · doi:10.1016/s0959-8049(11)70171-x · Cited by 5
Tumor MET expression profile predicts the outcome of non‐small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors
Chang, H. K., Zhang, X., Cho, B. C., Park, H., & Kim, J.-H. (2014) · Thoracic Cancer · doi:10.1111/1759-7714.12122 · Cited by 5
EGFR mutations in patients with non small-cell lung cancer in Bulgaria and treatment with gefitinib.
Damyanov, D., Koynov, K. D., Naseva, E., & Bichev, S. (2015) · PubMed · Cited by 5
Repurposing loperamide to overcome gefitinib resistance by triggering apoptosis independent of autophagy induction in KRAS mutant NSCLC cells
Tong, C. W. S., Wu, M., Yan, V. W., Cho, W. C. S., & To, K. K. W. (2020) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2020.100229 · Cited by 5
Treatment of Chronic Myelogenous Leukemia as a Paradigm for Solid Tumors: How Targeted Agents in Newly Diagnosed Disease Transformed Outcomes
Westin, J. R., Kantarjian, H. M., & Kurzrock, R. (2012) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2012.32.60 · Cited by 5
[Personalized targeted therapy for lung cancer].
Wu, K., House, L. K., Liu, W., & Cho, W. C. S. (2013) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2013.08.10 · Cited by 5
Divide and Conquer: Progress in the Molecular Stratification of Cancer
Tan, P. B. O. (2009) · Yonsei Medical Journal · doi:10.3349/ymj.2009.50.4.464 · Cited by 6
Antitumor activity of kinetochore-associated protein 2 siRNA against lung cancer patient-derived tumor xenografts
Makita, Y., Teratani, M., Murata, S., Hoashi, Y., Matsumoto, S., & Kawamata, Y. (2018) · Oncology Letters · doi:10.3892/ol.2018.7890 · Cited by 5
High-Penetrance Rare Variants Underlying Familial Lung Cancer Risk: Insights From Genetic Epidemiology of Lung Cancer Consortium
Liu, Y., Li, Y., Byun, J., Shaw, V. R., Pikielny, C. W., Peng, B., Cheng, C., Tsavachidis, S., Xiao, X., Zhu, D. K., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.12.004 · Cited by 4
Case report: Neuroendocrine breast carcinoma with a germline EGFR T790M mutation
Sagan, O. A., Rothstein, A., Jambunathan, B., Hadziahmetovic, M., Antoniolli, A., & Rashid, M. H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1176868 · Cited by 4
Ex vivobiomarkers: functional tools to guide targeted drug development and therapy
Clark, D. P. (2009) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.09.62 · Cited by 4
Multi-line treatment with tyrosine kinase inhibitors enabled in 4-year survival for patient with stage IV lung adenocarcinoma: a case report
Yin, Y., & Qin, J. (2020) · Annals of Palliative Medicine · doi:10.21037/apm-20-1514 · Cited by 4
Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives
Zukin, M. (2012) · Revista da Associação Médica Brasileira · doi:10.1016/s0104-4230(12)70190-2 · Cited by 4
Efficacy and safety of EGFR‑TKIs plus Shenqi Fuzheng injection for non-small cell lung cancer patients with EGFR-sensitive mutations
Wang, J., Chen, C.-S., Jia, Z., Miao, L., Xie, J., Pan, Z., Duan, Y., Liu, S., Hou, M.-J., & Ding, X. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04297-3 · Cited by 4
Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study
Kim, T., Choi, J., Ahn, M. S., Lee, H. W., Kang, S. Y., Choi, Y. W., Koh, Y. W., & Sheen, S. S. (2024) · BMC Cancer · doi:10.1186/s12885-023-11782-6 · Cited by 6
A validated high‐performance liquid chromatography–tandem mass spectrometry method for quantification of gefitinib and its main metabolites in xenograft mouse tumor: Application to a pharmacokinetics study
Zhao, C., Zheng, N., Yang, F., Han, S., & Li, P. (2019) · Biomedical Chromatography · doi:10.1002/bmc.4638 · Cited by 4
Management of patients with advanced non-small cell lung cancer: role of gefitinib
Govindan, R. (2010) · Biologics · doi:10.2147/btt.s4144 · Cited by 4
k-RAS mutations in non-small cell lung cancer patients treated with TKIs among smokers and non-smokers: a meta-analysis
Jiang, A.-G., & Lu, H. (2016) · Współczesna Onkologia · doi:10.5114/wo.2016.60068 · Cited by 6
Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma
Zhai, X., Zheng, Q., Yang, L., Zhu, Y., Li, J., Liu, Y., & Wang, Z. (2017) · Scientific Reports · doi:10.1038/s41598-017-01347-6 · Cited by 4
Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer
Cui, S., & Jiang, L. (2017) · Tumor Biology · doi:10.1177/1010428317705340 · Cited by 4
Positive PD‑L1 expression is predictive for patients with advanced EGFR wild‑type non‑small cell lung cancer treated with gemcitabine and cisplatin
Qiu, Y., Jiang, J., Zhang, M., & Qin, Y. (2019) · Oncology Letters · doi:10.3892/ol.2019.10302 · Cited by 4
Identification of drug resistance associated ncRNAs based on comprehensive heterogeneous network
Huang, Y., Zhou, S., Liu, H., Zhou, X., Yuan, M., Hou, F., Wang, L., & Jiang, W. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117256 · Cited by 4
SWOG S0023: What Meets the Eye May Be Only Half the Truth
Bhutani, M., Pathak, A., & Mao, L. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.4218 · Cited by 4
Design and Synthesis of 1,3,4-Oxadiazole–Quinazolinone Hybrids, Evaluation of Their Anticancer and Antimicrobial Activities, and Docking Studies
Suryanarayana, N. S., Sridhar, C., & Bindu, G. H. (2025) · Russian Journal of Organic Chemistry · doi:10.1134/s1070428024601997 · Cited by 3
Gefitinib: an “orphan” drug for non-small cell lung cancer
Ziogas, D. C., Liontos, M., Kyriazoglou, A. I., Tsironis, G., Bamias, A., & Dimopoulos, M. A. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1392852 · Cited by 3
Suppression of c-MET overcomes erlotinib resistance in tongue cancer cells
Huang, K., & Liu, D. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s167936 · Cited by 3
Osteopontin improves sensitivity to tyrosine kinase inhibitor in lung adenocarcinoma in vitro by promoting epidermal growth factor receptor phosphorylation
Wang, Y., Wang, Q., Yu, D., Song, C., Guo, Z., Liu, X., Chen, C., Yao, J., Wang, A., & Hu, W. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03731-2 · Cited by 3
Novel agents in invasive urothelial cancer.
Balar, A. V., & Milowsky, M. I. (2012) · PubMed · Cited by 3
Clinical Laboratory Results as Prognosis Marker in Advanced Stage Non-small Cell Lung Cancer (NSCLC) in Indonesia
Hanafi, A. R., Jayusman, A. M., Sutandyo, N., Kurniawati, S., Setiawan, L., Diandra, A., & Hidayat, K. (2022) · Cureus · doi:10.7759/cureus.29386 · Cited by 3
QT-Interval Prolongation, Torsades de Pointes, and Heart Failure With EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Systematic Review
Khokhar, B., Chiang, B., Iglay, K., Reynolds, K. R., Rodriguez‐Ormaza, N., Spalding, W. M., & Freedland, E. S. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.02.005 · Cited by 4
Treating EGFR-Mutated Oncogene-Addicted Advanced Non–Small-Cell Lung Cancer in the Era of Economic Crisis in Greece: Challenges and Opportunities
Fountzilas, E., Levva, S., Mountzios, G., Polychronidou, G., Maniadakis, N., Kotoula, V., & Fountzilas, G. (2018) · Journal of Global Oncology · doi:10.1200/jgo.18.00115 · Cited by 3
Genetically Engineered Mouse Models in Preclinical Anti-Cancer Drug Development
Sergio, Y., & Melinda, G. (2011) · InTech eBooks · doi:10.5772/30666 · Cited by 3
Treatment of Advanced Lung Cancer
Ou, S. I., & Ho, C. (2009) · Clinical Pulmonary Medicine · doi:10.1097/cpm.0b013e3181a3dbba · Cited by 3
Oncologist’s/haematologist’s view on the roles of pathologists for molecular targeted cancer therapy
Keller, U. B., von Bubnoff, N. C. C., Peschel, C., & Duyster, J. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01032.x · Cited by 3
Molecular imaging for detection of sensitivity and resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
Iommelli, F., Rosa, V. D., Fonti, R., & Vecchio, S. D. (2014) · Clinical and Translational Imaging · doi:10.1007/s40336-014-0050-6 · Cited by 4
Detection and characterization of circulating cell free tumor DNA in cancer patients with malignant solid tumors. Liquid biopsy: a new tool in molecular pathology?
Hinrichsen, T., Dworniczak, J. K., Wachter, O., Dworniczak, B., & Dockhorn‐Dworniczak, B. (2016) · Journal of Laboratory Medicine · doi:10.1515/labmed-2016-0035 · Cited by 3
Molecular Testing in Lung Cancer
Shiau, C. J., & Tsao, M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800886-7.00023-6 · Cited by 3
Pharmacogenomics and Personalized Medicine for Cancer
Dhawan, D., & Padh, H. (2013) · Springer eBooks · doi:10.1007/978-81-322-1184-6_11 · Cited by 3
Multi-center, randomized, double-blind, placebo-controlled, exploratory study to evaluate the efficacy and safety of HAD-B1 for dose-finding in EGFR positive and locally advanced or metastatic NSCLC subjects who need Afatinib therapy
Park, S.-J., Kang, H.-J., Jun, H.-J., Shin, S. H., & Yoo, H. (2020) · Medicine · doi:10.1097/md.0000000000018735 · Cited by 3
The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era
Spagnuolo, A., Muto, M., Monaco, F., Colantuoni, G., & Gridelli, C. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.12.24 · Cited by 3
Comprehensive analysis of clinicopathological profiles in adenosquamous carcinoma of the lung
Wang, Y. (2024) · American Journal of Translational Research · doi:10.62347/uxqc3380 · Cited by 2
TRAIL apoptotic pathway-targeted therapies for NSCLC.
Bellail, A. C., & Hao, C. (2012) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2012.02.02 · Cited by 2
Deep neural network for discovering metabolism-related biomarkers for lung adenocarcinoma
Fu, L., Li, M., Lv, J., Yang, C., Zhang, Z., Qin, S., Wan, L., Wang, X., & Chen, L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1270772 · Cited by 2
Three Polymorphs and Two Hydrates of a Multidrug Crystal Involving Gefitinib and Rhein: Characterization, Stability, and Solubility Aspects
Zhang, F., Long, X.-T., Ren, B.-Y., Dai, X.-L., Lu, T., & Chen, J. (2024) · Crystal Growth & Design · doi:10.1021/acs.cgd.4c00145 · Cited by 2
Establishment and Characterization of a Pair of Patient-derived Human Non-small Cell Lung Cancer Cell Lines from a Primary Tumor and Corresponding Lymph Node Metastasis.
Gebauer, F., Wicklein, D., Tachezy, M., Grob, T. J., Steinemann, D., Manukjan, G., Göhring, G., Schlegelberger, B., Maar, H., Izbicki, J. R., et al. (2016) · PubMed · Cited by 2
Clinical Trial Design in the Age of Molecular Profiling
Spira, A. I., & Edmiston, K. H. (2011) · Methods in molecular biology · doi:10.1007/978-1-60327-216-2_2 · Cited by 2
Self-citation
[Advanced research on T790M mutation in non-small cell lung cancer].
Li, H., Zhang, S., & Cheng, Y. (2013) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2013.06.08 · Cited by 2
Can kinomics and proteomics bridge the gap between pediatric cancers and newly designed kinase inhibitors?
van der Sligte, N. E., Kampen, K. R., & de Bont, E. S. J. M. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2019-7 · Cited by 2
Advanced lung adenocarcinoma in an EGFR-positive patient treated with Erlotinib for 52 months
Gaspar, I. G., Ladeira, I., Castro, A., Antunes, A., Barroso, A., & Parente, B. (2013) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2013.06.003 · Cited by 2
EGFR Mutation Testing in Non-Small Cell Lung Cancer
Sriram, K. B., Francis, S. M. S., Tan, M. E., Bowman, R., Yang, I. A., & Fong, K. M. (2010) · Current Respiratory Medicine Reviews · doi:10.2174/157339810793563776 · Cited by 2
Personalized Therapies for Cancer Treatment
Nair, L., & Gonzalez-Angulo, A. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-416603-5.00013-4 · Cited by 2
Biomarkers for Go/No Go Decisions
Markman, B., & Tabernero, J. M. (2012) · Springer eBooks · doi:10.1007/978-1-4419-9755-5_18 · Cited by 2
Guide to Targeted Therapies: EGFR mutations in NSCLC
Cappuzzo, F. (2014) · Springer eBooks · doi:10.1007/978-3-319-03059-3 · Cited by 3
EGFR mutations in lung cancer
Verdú, M., Trias, I., Roman, R. A., Rodón, N., Pubill, C., Calvo, M., García‐Peláez, B., Diaz, O., & Puig, X. (2016) · Revista Española de Patología · doi:10.1016/j.patol.2016.04.006 · Cited by 2
Relationship between driver gene mutations, their relative protein expressions and survival in non‐small cell lung carcinoma in Macao
Chan, K. I., Vong, H. T., Sin, L.-F., Yip, Y. C., Zhong, X. Y., & Wen, J. M. (2017) · The Clinical Respiratory Journal · doi:10.1111/crj.12670 · Cited by 2
Resistance of Colorectal Tumors to Anti-EGFR Antibodies
Trusolino, L., & Leto, S. M. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-67932-7_1 · Cited by 2
Impact of menopausal status and HER-2/neu protein on efficacy of EGFR-TKI in EGFR mutant patients with non-small cell lung cancer
Yin, Z., Tu, H., Fu, M., Zhong, W., An, S., Yan, H., Chen, H., Lin, H., & Wu, Y.-L. L. C. (2018) · Journal of Cancer · doi:10.7150/jca.25679 · Cited by 2
Molecular Testing in Lung Cancer
Mascaux, C., Tsao, M., & Hirsch, F. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52357-8.00018-4 · Cited by 2
Incorporating Pharmacogenomics in Drug Development
Yin, O. Q. P., & Vandell, A. G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812626-4.00003-6 · Cited by 3
Biology of Lung Cancer
Massion, P. P., Sequist, L. V. D., & Pao, W. J. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00051-8 · Cited by 3
Self-citation
The Value of Population Screening in Advancing Personalized Medicine in the Field of Lung Cancer
Mogenet, A., Greillier, L., & Tomasini, P. (2021) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s267437 · Cited by 2
Contribution of Ectodomain Mutations in Epidermal Growth Factor Receptor to Signaling in Glioblastoma Multiforme
Rojas, M. L. (2011) · Digital Commons-TMC (Texas Medical Center) · Cited by 2
The Diverse Diversity
Mok, T. S. K., & Lam, K. C. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31821972ed · Cited by 2

Authors: Sequist, L. V., Martins, R. G., Spigel, D., Grunberg, S. M., Spira, A., Jänne, P. A., Joshi, V. A., McCollum, D., Evans, T. L., Muzikansky, A., Kuhlmann, G. L., Han, M., Goldberg, J. S., Settleman, J., Iafrate, A. J., Engelman, J. A., Haber, D. A., Johnson, B. E., & Lynch, T. J.
Affiliations: Brigham and Women's Hospital (US)
From the Massachusetts General Hospital Cancer Center; Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital; Department of Pathology, Massachusetts General Hospital; Department of Biostatistics, Massachusetts General Hospital, Boston; Harvard Medical School/Partners Health Care Center for Genetics and Genomics, Cambridge, MA; University of Washington, Seattle, WA; Sarah Cannon Research Institute, Nashville, TN; Fletcher Allen Health Care, Burlington, VT; Fairfax-Northern...
ORCID: Sequist, Lecia V.
Martins, Renato G.
Spigel, David
Spira, Alexander
Evans, Tracey L.
Muzikansky, Alona
Han, Moon
Settleman, Jeffrey
Iafrate, A. John
Engelman, Jeffrey A.
Haber, Daniel A.
Johnson, Bruce E.
Lynch, Thomas J.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2008-05-20
Volume: 26
Issue: 15
Pages: 2442-2449
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2007.14.8494
OpenAlex: W2101329867
Cited by: 820
References: 46
Citations by year: 2026: 4 · 2025: 14 · 2024: 9 · 2023: 11 · 2022: 20 · 2021: 22 · 2020: 34 · 2019: 29 · 2018: 51 · 2017: 51 · 2016: 54 · 2015: 57 · 2014: 68 · 2013: 69 · 2012: 60
FWCI: 81.10
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: gefitinib, non-small cell lung cancer, EGFR mutation, first-line therapy, EGFR tyrosine kinase inhibitors, exon 19 deletion, L858R mutation, T790M mutation, MET amplification, progression-free survival, response rate, pneumonitis, genotype-directed therapy
MeSH terms: Gefitinib, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasm Staging, Prospective Studies, Quinazolines, Survival Rate, Central Nervous System Neoplasms, Treatment Outcome, In Situ Hybridization, Fluorescence, Carcinoma, Large Cell, Disease-Free Survival, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks